forms

SGX Pharmaceuticals forms collaboration to commercialize BCR-ABL inhibitors for the treatment of chronic myelogenous leukemia.: An article from: BIOTECH Patent News by Unknow

SGX Pharmaceuticals forms collaboration to commercialize BCR-ABL inhibitors for the treatment of chronic myelogenous leukemia.: An article from: BIOTECH Patent News by Unknow

Continue reading

User tags:

  • SGX Pharmaceuticals forms collaboration to commercialize BCR-ABL inhibitors for the treatment of chronic myelogenous leukemia : An article from: BIOTECH Patent News